Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData, Phase III drugs for Systemic Lupus Erythematosus have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Deucravacitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deucravacitinib overview

Deucravacitinib (Sotyktu) is a deuterium first-in-class molecule, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. It is formulated as film-coated tablets, tablets for the oral route of administration. Sotyktu is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

BMS-986165 is under development for the treatment of systemic lupus erythematosus, subacute cutaneous lupus erythematosus, psoriatic arthritis, severe crohn's disease, alopecia areata, ulcerative colitis and moderate to severe plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, autoimmune disorders and discoid lupus erythematosus. The drug candidate is administered orally as a solution. The drug candidate targets tyrosine kinase 2 (TYK2).

It was under development for the treatment of lupus nephritis.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

For a complete picture of Deucravacitinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.